What is DMRA's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 1.30B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for DMRA?

P/E (TTM) is n/a and 52-week range is $16.50 to $34.89 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s DMRA figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for DMRA?

The company profile lists net income (TTM) near $-8.58B, EPS (TTM) near $-139.34 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Damora Therapeutics Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Waltham, Massachusetts, US, 61.5M shares outstanding, ISIN US36322Q2066 when available from company profile and filing metadata.

Chartloom

Please enable JavaScript to continue using this application.

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Damora Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in developing novel small molecule therapeutics that are designed to target the biological processes that lie at the heart of cancer and fibrotic diseases. The company is headquartered in Waltham, Massachusetts and currently employs 7 full-time employees. The company went IPO on 2020-10-29. The firm is engaged in the advancing a new generation of biologics to treat mutant calreticulin-driven myeloproliferative neoplasms, including essential thrombocythemia and myelofibrosis, where there is significant medical need for disease-modifying treatments. The company offers a multiple programs including asset, DMR-001, an investigational monoclonal antibody therapy targeting mutCALR. DMR-001 was designed to exclusively bind to mutCALR with exquisite selectivity, potency, and extended half-life, with potential to enable convenient, infrequent subcutaneous dosing.

Employees

Website

galecto.com/

IPO

2020-10-29

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)